Analgesic effect of a broad-spectrum dihydropyridine inhibitor of voltage-gated calcium channels


Gadotti V. M. , Bladen C., Zhang F. X. , Chen L., GÜNDÜZ M. G. , ŞİMŞEK R. , ...Daha Fazla

PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, cilt.467, ss.2485-2493, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 467 Konu: 12
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1007/s00424-015-1725-1
  • Dergi Adı: PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
  • Sayfa Sayıları: ss.2485-2493

Özet

Voltage-activated calcium channels are important facilitators of nociceptive transmission in the primary afferent pathway. Consequently, molecules that block these channels are of potential use as pain therapeutics. Our group has recently reported on the identification of a novel class of dihydropyridines (DHPs) that included compounds with preferential selectivity for T-type over L-type channels. Among those compounds, M4 was found to be an equipotent inhibitor of both Cav1.2 L- and Cav3.2 T-type calcium channels. Here, we have further characterized the effects of this compound on other types of calcium channels and examined its analgesic effect when delivered either spinally (i.t.) or systemically (i.p.) to mice. Both delivery routes resulted in antinociception in a model of acute pain. Furthermore, M4 was able to reverse mechanical hyperalgesia produced by nerve injury when delivered intrathecally. M4 retained partial activity when delivered to Cav3.2 null mice, indicating that this compound acts on multiple targets. Additional whole-cell patch clamp experiments in transfected tsA-201 cells revealed that M4 also effectively blocks Cav3.3 (T-type) and Cav2.2 (N-type) currents. Altogether, our data indicate that broad-spectrum inhibition of multiple calcium channel subtypes can lead to potent analgesia in rodents.